Paige on Thursday announced a partnership with OptraScan to streamline digital pathology technology adoption in the U.S., EU, and U.K.
The companies aim to reduce barriers to the adoption of digitizing glass pathology slides, which will in turn enhance workflows in pathology and oncology, Paige said.
“This collaboration is an important step in our mission to unlock the full potential of [artificial intelligence (AI)] in routine clinical use and provide healthcare professionals with precise insights to help patients get the most effective care,” Andy Moye, CEO of Paige, said in a statement.
About OptraSCAN, Inc.
OptraSCAN® are pioneers in the On-Demand Digital Pathology® System, focused on delivering fully integrated, affordable solutions that will maximize your return on investment and improve the performance of your pathology services. An ISO 13485 certified company and CE marked whole slide scanners for IVD use, OptraSCAN is working to eliminate the barriers to “Go Digital” no matter the size of the pathology lab, the lab’s throughput or global location.
OptraSCAN’s end-to-end digital pathology solution provides effective acquisition of whole slide images, viewing, storing, real-time sharing, reporting and AI & ML based Image analysis solutions via On-Demand or outright purchase model.
Please visit www.optrascan.com